Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Prazosin HCl (Furazosin, cp12299-1; cp-12299-1; Minipress, Peripress), the hydrochloride salt of prazosin, is a potent and competitive alpha-1 adrenoceptor antagonist with antihypertensive effects. It has been used to treat heart failure, hypertension, pheochromocytoma, Raynaud disease, prostratic hypertrophy, high blood pressure, or benign prostatic hyperplasia (BPH). It has also been used to treat urinary retention. Only in the presence of eNOS does prazosin cause a notable rise in VEGF concentration in endothelial cells and angiogenesis. Prazosin attaches itself to the α1-adrenergic receptors found on the smooth muscle cells encircling all major blood vessels.
Targets |
α adrenergic receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C19H22CLN5O4
|
|
---|---|---|
Molecular Weight |
419.86
|
|
Exact Mass |
419.14
|
|
Elemental Analysis |
C, 54.35; H, 5.28; Cl, 8.44; N, 16.68; O, 15.24
|
|
CAS # |
19237-84-4
|
|
Appearance |
White to off-white crystalline powder
|
|
SMILES |
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl
|
|
InChi Key |
WFXFYZULCQKPIP-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H
|
|
Chemical Name |
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3817 mL | 11.9087 mL | 23.8175 mL | |
5 mM | 0.4763 mL | 2.3817 mL | 4.7635 mL | |
10 mM | 0.2382 mL | 1.1909 mL | 2.3817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02965027 | Active Recruiting |
Drug: Prazosin Drug: Placebos |
Post-Traumatic Headache | Seattle Institute for Biomedical and Clinical Research |
November 29, 2016 | Phase 4 |
NCT04793685 | Recruiting | Drug: Prazosin Behavioral: 12-Step Facilitation with Relapse Prevention and Contingency Management |
Alcohol Withdrawal | Yale University | July 1, 2021 | Phase 1 Phase 2 |
NCT03539614 | Recruiting | Drug: Prazosin Drug: Placebo |
Posttraumatic Stress Disorder | VA Office of Research andCDevelopment | June 4, 2018 | Phase 3 |
NCT04721353 | Recruiting | Drug: Prazosin Hydrochloride | Cannabis Dependence Cannabis Use Disorder |
VA Puget Sound Health Care System |
November 9, 2020 | Phase 4 |
NCT06147622 | Not yet recruiting | Drug: KT110 Drug: Prazosin + cyproheptadine |
Alcohol Use Disorder | Kinnov Therapeutics | February 2024 | Phase 1 |
Effect of prazosin or guanfacine on yohimbine-induced reinstatement and effect of prazosin on intermittent footshock-induced reinstatement. Psychopharmacology (Berl) . 2011 Nov;218(1):89-99. td> |
Effect of prazosin or guanfacine on food-reinforced responding. Psychopharmacology (Berl) . 2011 Nov;218(1):89-99. td> |
Upregulation of eNOS in skeletal muscles of C57BL/6 mice in response to prazosin. Am J Physiol Heart Circ Physiol . 2004 Nov;287(5):H2300-8. td> |
Quantification of VEGF in EDL muscle homogenates of C57BL/6 mice and eNOS-knockout mice during 14 days of prazosin administration. Am J Physiol Heart Circ Physiol . 2004 Nov;287(5):H2300-8. td> |